160 related articles for article (PubMed ID: 16721785)
1. BRAF and KRAS mutations in prostatic adenocarcinoma.
Cho NY; Choi M; Kim BH; Cho YM; Moon KC; Kang GH
Int J Cancer; 2006 Oct; 119(8):1858-62. PubMed ID: 16721785
[TBL] [Abstract][Full Text] [Related]
2. Molecular Characterization of KRAS, BRAF, and EGFR Genes in Cases with Prostatic Adenocarcinoma; Reporting Bioinformatics Description and Recurrent Mutations.
Salmaninejad A; Ghadami S; Dizaji MZ; Golchehre Z; Estiar MA; Zamani MR; Ebrahimzadeh-Vesal R; Nowroozi MR; Shakoori A
Clin Lab; 2015; 61(7):749-59. PubMed ID: 26299074
[TBL] [Abstract][Full Text] [Related]
3. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.
Yuen ST; Davies H; Chan TL; Ho JW; Bignell GR; Cox C; Stephens P; Edkins S; Tsui WW; Chan AS; Futreal PA; Stratton MR; Wooster R; Leung SY
Cancer Res; 2002 Nov; 62(22):6451-5. PubMed ID: 12438234
[TBL] [Abstract][Full Text] [Related]
4. Lack of BRAF activating mutations in prostate adenocarcinoma: a study of 93 cases.
Liu T; Willmore-Payne C; Layfield LJ; Holden JA
Appl Immunohistochem Mol Morphol; 2009 Mar; 17(2):121-5. PubMed ID: 18987552
[TBL] [Abstract][Full Text] [Related]
5. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.
Schmid K; Oehl N; Wrba F; Pirker R; Pirker C; Filipits M
Clin Cancer Res; 2009 Jul; 15(14):4554-60. PubMed ID: 19584155
[TBL] [Abstract][Full Text] [Related]
6. Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma.
Kang S; Kim HS; Seo SS; Park SY; Sidransky D; Dong SM
Gynecol Oncol; 2007 Jun; 105(3):662-6. PubMed ID: 17360030
[TBL] [Abstract][Full Text] [Related]
7. The histopathology of BRAF-V600E-mutated lung adenocarcinoma.
Yousem SA; Nikiforova M; Nikiforov Y
Am J Surg Pathol; 2008 Sep; 32(9):1317-21. PubMed ID: 18636014
[TBL] [Abstract][Full Text] [Related]
8. Identification of frequent BRAF copy number gain and alterations of RAF genes in Chinese prostate cancer.
Ren G; Liu X; Mao X; Zhang Y; Stankiewicz E; Hylands L; Song R; Berney DM; Clark J; Cooper C; Lu YJ
Genes Chromosomes Cancer; 2012 Nov; 51(11):1014-23. PubMed ID: 22833462
[TBL] [Abstract][Full Text] [Related]
9. Mutations in the RAS/RAF/MAP kinase pathway commonly occur in gallbladder adenomas but are uncommon in gallbladder adenocarcinomas.
Pai RK; Mojtahed K; Pai RK
Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):133-40. PubMed ID: 21307665
[TBL] [Abstract][Full Text] [Related]
10. Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma.
Sommerer F; Vieth M; Markwarth A; Röhrich K; Vomschloss S; May A; Ell C; Stolte M; Hengge UR; Wittekind C; Tannapfel A
Oncogene; 2004 Jan; 23(2):554-8. PubMed ID: 14724583
[TBL] [Abstract][Full Text] [Related]
11. KRAS and BRAF mutations in prostate carcinomas of Chinese patients.
Shen Y; Lu Y; Yin X; Zhu G; Zhu J
Cancer Genet Cytogenet; 2010 Apr; 198(1):35-9. PubMed ID: 20303012
[TBL] [Abstract][Full Text] [Related]
12. PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events.
Agell L; Hernández S; Salido M; de Muga S; Juanpere N; Arumí-Uria M; Menendez S; Lorenzo M; Lorente JA; Serrano S; Lloreta J
Mod Pathol; 2011 Mar; 24(3):443-52. PubMed ID: 21113138
[TBL] [Abstract][Full Text] [Related]
13. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas.
Fransén K; Klintenäs M; Osterström A; Dimberg J; Monstein HJ; Söderkvist P
Carcinogenesis; 2004 Apr; 25(4):527-33. PubMed ID: 14688025
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
Baldus SE; Schaefer KL; Engers R; Hartleb D; Stoecklein NH; Gabbert HE
Clin Cancer Res; 2010 Feb; 16(3):790-9. PubMed ID: 20103678
[TBL] [Abstract][Full Text] [Related]
15. Low mutation percentage of KRAS and BRAF genes in Brazilian anal tumors.
Bidinotto LT; Véo CA; Loaiza EA; De França AP; Lorenzi AT; Rosa LA; De Oliveira CM; Levi JE; Scapulatempo-Neto C; Longatto-Filho A; Reis RM
Mol Med Rep; 2016 Oct; 14(4):3791-7. PubMed ID: 27573925
[TBL] [Abstract][Full Text] [Related]
16. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status.
Pappa KI; Choleza M; Markaki S; Giannikaki E; Kyroudi A; Vlachos G; Voulgaris Z; Anagnou NP
Gynecol Oncol; 2006 Mar; 100(3):596-600. PubMed ID: 16256179
[TBL] [Abstract][Full Text] [Related]
17. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
Ji H; Wang Z; Perera SA; Li D; Liang MC; Zaghlul S; McNamara K; Chen L; Albert M; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Thomas RK; Garraway LA; Jänne PA; Johnson BE; Chin L; Wong KK
Cancer Res; 2007 May; 67(10):4933-9. PubMed ID: 17510423
[TBL] [Abstract][Full Text] [Related]
18. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
19. Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma.
Krol LC; 't Hart NA; Methorst N; Knol AJ; Prinsen C; Boers JE
Eur J Cancer; 2012 May; 48(7):1108-15. PubMed ID: 22446020
[TBL] [Abstract][Full Text] [Related]
20. Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes.
Immervoll H; Hoem D; Kugarajh K; Steine SJ; Molven A
Virchows Arch; 2006 Jun; 448(6):788-96. PubMed ID: 16598499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]